Noticias y Actividades de Bicycle Therapeutics
Presencia
Bicycle Therapeutics es una empresa que cotiza bajo el símbolo de cotización BCYC (US).
Ejecutivos
Ver el organigrama con sus 24 ejecutivos principales
Biografías más buscadas en Bicycle Therapeutics
- Kevin Lee, Chief Executive Officer and Director
- Jose-Carlos Gutierrez-Ramos, Director
- Stephen Sands, Director
Recientes movimientos de ejecutivos en Bicycle Therapeutics
- Eric Westin que ha sido Senior Vice President, Clinical Development and Translational Sciences, ha ascendido a Chief Medical Officer (noticia publicada el 28 de marzo de 2025).
- Jim MacDonald-Clink que ha sido Vice President, Business Development, ha ascendido a Senior Vice President, Head of Business Development (noticia publicada el 28 de marzo de 2025).
- Pierre Legault, Chairman of the Board, ha dejado la empresa (noticia publicada el 28 de marzo de 2025).
Haga clic aquí para ver otros movimientos en Bicycle Therapeutics
Crear su alerta
para seguir los movimientos de los ejecutivos en Bicycle Therapeutics.
Biotecnología
Bicycle Therapeutics tiene 2.347 competidores entre los que se incluyen Eurofins (Luxemburgo), Lonza (Suiza) y Johnson & Johnson Innovative Medicine DIA (Estados Unidos).
Popular M&A news in Biotecnología
- Attovia Therapeutics acaba de anunciar una recaudación de fondos de 90 millones de dólares. (publicado el 21 de abril de 2025).
- Transcarent and Accolade have merged (publicado el 9 de abril de 2025)..
- Kashiv BioSciences acaba de anunciar una recaudación de fondos de 150 millones de dólares. (publicado el 7 de abril de 2025).
Otros contactos sugeridos en el sector Biotecnología
Noticias
Últimos comunicados de prensa de Bicycle Therapeutics
- Press Releases | Bicycle Therapeutics
- Bicycle Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update | Bicycle Therapeutics
- Bicycle Therapeutics Announces Publication of Article Highlighting Preclinical Data from BT7480 Program in the Journal of Medicinal Chemistry | Bicycle Therapeutics
- Bicycle Therapeutics Announces Further Expansion of Genentech Immuno-Oncology Collaboration | Bicycle Therapeutics
- Bicycle Therapeutics Announces First Patient Dosed in Expansion Cohorts of Phase I/II Trial of Bicycle® Toxin Conjugate BT5528 in Patients with Advanced Solid Tumors Associated with EphA2 Expression | Bicycle Therapeutics
- Bicycle Therapeutics to Participate in the Jefferies Healthcare Conference | Bicycle Therapeutics
- Bicycle Therapeutics to Present Trials in Progress Poster Featuring BT7480 Phase I/II Clinical Trial at the 2022 ASCO Annual Meeting | Bicycle Therapeutics
- Bicycle Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update | Bicycle Therapeutics
- Bicycle Therapeutics Announces Interim BT8009 Phase I Clinical Trial Results at the 2022 AACR Annual Meeting | Bicycle Therapeutics
- Bicycle Therapeutics to Present Interim BT8009 Phase I Clinical Trial Results at the 2022 AACR Annual Meeting | Bicycle Therapeutics
- View more press releases Close
Redes sociales sobre Bicycle Therapeutics
- Bicycle Therapeutics en Wikipedia, Google News y Yahoo Finance
- Bicycle Therapeutics en LinkedIn, Twitter y YouTube
